// App-Quantinova.ai

SAT0134 : COMPARATIVE RISK OF CANCER ASSOCIATED WITH FIRST-LINE DMARDS USE IN RHEUMATOID ARTHRITIS: REAL WORLD EVIDENCE FROM THE OHDSI NETWORK

Researchers

Presenter

  • T. Duarte-Salles

Principal Investigators

  • M. Recalde

  • J. Weaver

  • E. Burn

  • K. Marinier

  • Y. Daz

  • B. Illingens

  • D. Vizcaya

  • K. Chatzidionysiou

  • P. Ryan

  • D. Prieto-Alhambra

Medical Centers

  • IDIAP Jordi Gol, Barcelona, Spain

  • Janssen Research and Development, Titusville, New Jersey, United States of America

  • University of Oxford, Oxford, United Kingdom

  • Servier, Paris, France

  • Harvard Medical School - Boston - United States of America

  • Bayer Hispania, Barcelona, Spain

  • Karolinska Institutet, Stockholm, Sweden

Locations

  • Spain

  • United States

  • United Kingdom

  • France

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • sulphasalazine

  • Methotrexate

  • HWA-486

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved